by Shana Cristoferi | Jun 27, 2019 | Appili Therapeutics, IMV Inc., News, SONA NanoTech
Read full Entrevestor article here The stock market is looming larger in the Atlantic Canadian startup community than it ever has before, as several leading companies are choosing public markets as the best option to secure long-term financing. Just in the past week,...
by Shana Cristoferi | Jun 26, 2019 | Appili Therapeutics, NeuroQuest, News
See full Entrevestor article here Shares of Halifax drug discovery company Appili Therapeutics Inc. begin trading on the TSX Venture exchange today. The company, whose long-term goal is to produce drugs that can combat antibiotic-resistant viruses, issued...
by administrator | Oct 2, 2018 | Appili Therapeutics, News
Read the original article here. Appili Therapeutics, a Halifax-based drug development company, has appointed its first ever Chief Scientific Officer. Armand Balboni, the new CSO, will be responsible for the company’s clinical and scientific strategy as well as...
by administrator | Oct 2, 2018 | Appili Therapeutics, News
See the original post here. HALIFAX, Nova Scotia, October 1, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, has named Dr. Armand Balboni as its first Chief Scientific...
by administrator | Jul 30, 2018 | Appili Therapeutics, News
See original article here New Antibiotic Formulation Designed to Treat Parasitic and Anaerobic Bacterial Infections; Appili Will Use Study Data as Basis for NDA Filing HALIFAX, Nova Scotia, July 30, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”) announced...
by administrator | Apr 18, 2018 | Appili Therapeutics, News
See original story here Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that it will participate in this year’s annual Bloom Burton & Co. Healthcare Investor Conference....
